DailyUpdates for Breaking Research
DailyUpdates features breaking research judged by LeadDiscovery's editorial team to be of key importance to drug development. Papers are selected from over 10,000 published each week from most pear reviewed journals.
A list of headline articles featured over the past week are listed below.
To submit you paper to be listed on DailyUpdates contact LeadDiscovery.
Research featured over the past 5 days
- Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models.
- A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
- An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials.
- Effect on bleeding, time to revascularization, and one-year clinical outcomes of the radial approach during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
- LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via up-regulation of VHL in a colon cancer cell line.
- One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
- Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives.
- A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors.
- Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
- Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions.
- Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C.
- A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
- Dimethyl-carbamic Acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine-1-Carbonyl)-Phenyl Ester: A Novel Multi-Target Therapeutic Approach to Neuroprotection.
- Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
- Angiotensin-converting enzyme (ACE) inhibition down regulates the pro-atherogenic chemokine receptor 9 (CCR9) - chemokine ligand 25 (CCL25) axis.
- Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268.
- NanoMonitor: a miniature electronic biosensor for glycan biomarker detection.
- Tapering clonazepam in patients with panic disorder after at least 3 years of treatment.
- Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.